Devil’s Claw is a perennial plant with creeping stems that bear thorny fruit. Indigenous to South Africa, it is a fearsome looking fruit (hence the name) which has been proven, scientifically, to alleviate pain caused by Arthritis and inflammation.
“Regarded in natural medicine as a natural treatment for inflammatory joint disorders. It may be equally effective as allopathic therapies, such as non-steroidal anti-inflammatory drugs, or may allow for dose reductions of cessation of these drugs in some patients.” Source: (Gagnier JJ, Chrubasik S, Manheimer E. Harpgophytum procumbens for Osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004;4:13)
HEALTH BENEFITS OF NATURMADE's DEVIL'S CLAW:
- Eases the aches and pains of rheumatism and arthritis
- May cure digestive disorders in a manner similar to bitters, and reduce gastrointestinal upset
- The analgesic and anti-inflammatory properties of Devil’s Claw are used to treat Arthritis, Osteoarthritis, Fibrositis, Gout, Lumbago, Myalgia, Sciatica and Rheumatic disease
- Treatment of Atherosclerosis (hardening of the arteries)
- Eases heart burn
- Can treat fever & migraines
The greatest efficacy observed, has been in the treatment of semi-chronic rather than acute pain. Devil’s Claw is excellent for on-going joint pain relief.
Devil's Claw is regarded as safe to take in pregnancy or whilst breastfeeding, however, as a potent digestive tonic herb, it may cause an upset stomach when used in higher doses. It is therefore recommended to be avoided if there is a sensitive or inflamed digestive lining such as in peptic ulcers.
DID YOU KNOW?
In a randomised study in patients with back pain, treatment with Devil's claw extract (equivalent to 6gms of root and containing 50mg of harpagoside) for 4 weeks, demonstrated a significant reduction of pain compared to placebo and more patients in the treatment group, were pain free at the end of the study. A similar study confirmed these results finding more patients receiving the Devil's claw, pain free at the end of another 4 week trial. Source: (Chrubasik S et al: Eur J Anaesthesiol 16(2):118-129, 1999)